Please assess the completion status of the following clinical trial:

Trial Title: CASAD for Severe Diarrhea in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cancer patients presenting to the EC or an acute care clinic for NCI grade \>/= 2 diarrhea~2. Able to understand the description of the study and give informed consent~3. Patients must be willing to and capable of providing frequent assessments for the duration of the study~4. English-speaking~Exclusion Criteria:~1. Patients will not be approached while they have : a) evidence of fever or severe abdominal pain, melena, overt blood in stool; b) any clinical suspicion or evidence of peritonitis or bowel perforation; c) s/p allogenic stem cell transplant~2. Patients will not be approached if the EC physician thinks that the diarrhea is due to Crohn's disease, ulcerative colitis, Celiac disease, graft-versus-host disease, short-gut syndrome, neuroendocrine paraneoplastic syndromes (e.g., MEN, VIPomas, etc.), or malabsorption syndromes~3. Patients who are status post stem cell transplantation (both autologous or allogenic)~4. Patients who are status post immunotherapy (including those who are receiving or have received ipilimumab)~5. Patients participating in other clinical trials for diarrhea~6. Patients with a known allergy to any components of the CASAD formulation~7. Patients whose current medication schedule would not permit an approximate 2 hour window between administration of CASAD and other scheduled medications~8. Patients who cannot comply with medications~9. Patients taking any clay products~10. Patients with radiological evidence of megacolon, intraperitoneal free air, pneumatosis intestinalis, or fecal impaction~11. History of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up~12. Patients who are pregnant~13. Patients less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcium Alumina-Silicate (CASAD) (Type: EXPERIMENTAL): CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).